Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reduced exposure to calcineurin inhibitors in renal transplantation.
Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF; ELITE-Symphony Study. Ekberg H, et al. Among authors: hugo c. N Engl J Med. 2007 Dec 20;357(25):2562-75. doi: 10.1056/NEJMoa067411. N Engl J Med. 2007. PMID: 18094377 Free article. Clinical Trial.
Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial.
Guba M, Pratschke J, Hugo C, Krämer BK, Nohr-Westphal C, Brockmann J, Andrassy J, Reinke P, Pressmar K, Hakenberg O, Fischereder M, Pascher A, Illner WD, Banas B, Jauch KW; SMART-Study Group. Guba M, et al. Among authors: hugo c. Transplantation. 2010 Jul 27;90(2):175-83. doi: 10.1097/TP.0b013e3181e11798. Transplantation. 2010. PMID: 20463641 Clinical Trial.
Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation.
Guba M, Pratschke J, Hugo C, Krämer BK, Pascher A, Pressmar K, Hakenberg O, Fischereder M, Brockmann J, Andrassy J, Banas B, Jauch KW; SMART-Study Group. Guba M, et al. Among authors: hugo c. Transpl Int. 2012 Apr;25(4):416-23. doi: 10.1111/j.1432-2277.2012.01432.x. Epub 2012 Feb 10. Transpl Int. 2012. PMID: 22320241 Free article.
Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
Sommerer C, Duerr M, Witzke O, Lehner F, Arns W, Kliem V, Ackermann D, Guba M, Jacobi J, Hauser IA, Stahl R, Reinke P, Rath T, Veit J, Mehrabi A, Porstner M, Budde K; HERAKLES Study Group. Sommerer C, et al. Am J Transplant. 2018 Dec;18(12):2965-2976. doi: 10.1111/ajt.14897. Epub 2018 Jun 3. Am J Transplant. 2018. PMID: 29722128 Free article. Clinical Trial.
Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial.
Marks WH, Mamode N, Montgomery RA, Stegall MD, Ratner LE, Cornell LD, Rowshani AT, Colvin RB, Dain B, Boice JA, Glotz D; C10-001 Study Group. Marks WH, et al. Am J Transplant. 2019 Oct;19(10):2876-2888. doi: 10.1111/ajt.15364. Epub 2019 Apr 19. Am J Transplant. 2019. PMID: 30887675 Free PMC article. Clinical Trial.
266 results